Evaluating the Evolving Real-World Adverse Events of GLP-1RAs Using FDA Adverse Event Reporting System (FAERS) - PubMed
4 days ago
- #Adverse Events
- #Pharmacovigilance
- #GLP-1RAs
- Study evaluates adverse events (AEs) linked to GLP-1RAs using FDA Adverse Event Reporting System (FAERS).
- Analysis includes FAERS reports from 2012 to 2025, focusing on five commonly prescribed GLP-1RAs.
- Most frequent AEs were gastrointestinal, nutritional, metabolic, and psychiatric disorders.
- In diabetes use, GLP-1RAs associated with retinopathy, hearing loss, and cataracts.
- For weight management/obesity, nutritional, metabolic, and psychiatric AEs were predominant.
- An open-access portal for AE exploration is available at http://glp1.tanlab.org.
- Findings highlight the need for careful clinical monitoring and long-term safety evaluation of GLP-1RAs.